Alabama Alzheimer's task force could propose tax credit for caregivers
Rep. Ginny Shaver, R-Leesburg, chairs the Alzheimer's Task Force subcommittee on advocacy and policy on March 18, 2025 in Montgomery, Ala. (Alander Rocha/Alabama Reflector)
A state committee looking at Alzheimer's policy is considering proposing a new tax credit to assist caregivers with expenses related to adult incontinence supplies, citing the financial burden of Alzheimer's and dementia care.
The proposal, discussed at a Tuesday meeting of the advocacy and policy subcommittee, aims to build on previously proposed legislation to provide tax relief for mothers and families with newborns with essentials such as diapers and baby formulas.
'We serve a lot of people with dementia, and all of them are in need of incontinence supplies,' said Anna Pritchett, state director for advocacy at AARP Alabama, adding that the costs add up quickly. 'Why don't we piggyback on that and just say, also including maybe people over the age of [a certain limit]?'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Alabama in 2022 had the second highest mortality rate from Alzheimer's disease, behind only Mississippi, at 46.8 per 100,000 people, according to the Centers for Disease Control and Prevention. Alzheimer's disease was the sixth-leading cause of death in the state in 2023, remaining unchanged from 2020. Different factors contribute to the high mortality rate, but it is mostly due to poor health access in rural parts of the state, primarily in the Black Belt, a region with some of the highest rates of Alzheimer's in the state.
Task force proposes new strategies to expand Alzheimer's care and research in Alabama
The Alzheimer's Association estimated that slightly over 100,000 people over 65 in Alabama living with Alzheimer's in 2020, or about 12% of that population.
Rep. Ginny Shaver, R-Leesburg, the chair of the committee, said that a bill addressing tax credits for infant supplies is already under consideration and will be introduced soon. The bill was introduced in the 2024 session but failed to pass before the end of the session. Shaver said that the timing could allow for an amendment to expand eligibility to seniors.
'We've got that bill coming up. I might be able to make that happen right now,' they said.
The Legislature is scheduled to hold its 15th legislative day, the midpoint of the 2025 session, on Wednesday.
Advocates said that financial relief is essential, as the cost of caring for an aging loved one can be not only overwhelming but also expensive.
Public awareness of available support remains a significant concern, with committee members saying there is still a significant need for better outreach and education. Members proposed a website that would serve as a hub for caregivers to get information on available services and support.
'Most people don't even know there's an [assisted living communities],' said Christy deGraffenried, vice president of governmental relations for the Alabama Nursing Home Association 'Then there's nursing homes, then there's home health. They don't even understand the basics of what are the levels of care.'
The task force was established in 2023 by a House Joint Resolution and tasked with establishing recommendations on how to improve the state's care system for Alzheimer's and other dementia-related diseases. Task force members will meet at the end of the month to propose recommendations to the Legislature and Gov. Kay Ivey by May 5.
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer's disease
PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB'S POTENTIAL FOR THE TREATMENT OF ALZHEIMER'S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION THIS PUBLICATION CORROBORATES NEW ANALYSIS FROM THE CLINICAL PHASE 2B/3 STUDY SHOWING COGNITIVE IMPROVEMENT UNDER MASITINIB TREATMENT PHASE 3 CLINICAL STUDY WITH MASITINIB AS A DISEASE-MODIFYING THERAPY FOR ALZHEIMER'S DISEASE HAS BEEN AUTHORIZED BY THE FDA AND KEY EU COUNTRIES Paris, June 23, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that a new peer-reviewed study from an independent research team based in China (Guangdong Pharmaceutical University and Sun Yat-sen University) presents new evidence showing that masitinib offers a promising new approach to treating Alzheimer's disease, specifically the most common form, sporadic Alzheimer's disease (sAD), which accounts for over 95% of all cases. Masitinib is a highly innovative drug for Alzheimer's disease because unlike the majority of drug development research in this indication, masitinib targets the brain's innate immune system, including mast cells and microglia. The positioning of masitinib as a treatment of Alzheimer's disease is also different from other drugs. New evidence from peer-reviewed study This new publication is accessible online from the Neuroscience Letters journal website at: [1] In the study, researchers used a well-established mouse model that mimics the cognitive and behavioral symptoms of human sAD. When treated with masitinib, the mice showed marked improvements in memory, learning, sense of smell, and anxiety-like behaviors, all of which are early indicators of Alzheimer's progression. The research also revealed that masitinib: • Reduced toxic brain proteins such as hyperphosphorylated Tau. • Alleviated synaptic dysfunction and morphological damage, i.e., it protected synapses, which are essential for brain cell communication. • Suppressed microglial activation, which in turn inhibited the NF-κB/NLRP3/caspase-1 signaling axis, a key inflammatory signaling cascade linked to Alzheimer's disease, thereby suppressing inflammation in the brain of sAD mice. The authors emphasized that this is the first study to demonstrate that masitinib attenuates sporadic Alzheimer's disease pathology through dual mechanisms of cognitive enhancement and neuroprotection. Professor Olivier Hermine, MD, President of the Scientific Committee of AB Science and member of the Académie des Sciences in France said, 'These new, independent findings provide strong evidence supporting masitinib as a promising disease-modifying therapy for sporadic Alzheimer's disease and perfectly compliment previously published clinical and preclinical data for masitinib in this indication.' New data from phase 2B/3 study in patients with mild Alzheimer's disease It has previously been shown that masitinib enhances cognitive function and synaptic integrity in a familial Alzheimer's disease mouse model [2]. Moreover, randomized, placebo-controlled, phase 2 and phase 2B/3 studies demonstrated that masitinib (4.5 mg/kg/day) can effectively delay or mitigate the progression of dementia [3,4]. Clinical and preclinical study findings have also been summarized in a review article [5], with the authors concluding that 'all research studies revealed positive effects concerning the cognitive functions in Alzheimer's disease and generally with good safety and tolerability'. New analysis from the completed phase 2B/3 study (AB09004), shows that masitinib treatment may not only slow down worsening of cognition in patients with mild Alzheimer's disease, but actually improves it over the treatment period of 24 weeks. Indeed, study AB09004 included patient with both mild and moderate AD (MMSE [12 - 25]). In the overall study population, which included patient with both mild and moderate AD (MMSE [12 - 25]), masitinib 4.5 mg/kg/day plus standard of care (memantine and anticholinesterase) demonstrated a significant reduction in cognitive impairment (ADAS-Cog LS Mean Diff = -2.15; p=0.0003) compared with standard of care alone. However, the clinical benefit on ADAS-Cog was greater in patients with mild impairment (LS Mean Diff = -2.89 ; p=0.0008) than in patients with moderate impairment (LS Mean Diff = -1.74; p=0.0284). Notably, there was a meaningful improvement in cognitive function between baseline and week 24 in the mild AD subgroup under masitinib treatment (LS Mean = -2.47), while it remained stable in the control arm (LS Mean = -0.42), as presented in the table below. ADAS-COG Change from Baseline to Week 24 N LS Mean LS Mean Diff.(97.51% CI) p-value Mild and moderate AD patients Masitinib 4.5 mg/kg/day + SoC 182 -1.45 -2.15(-3.48, -0.81) 0.0003 Placebo + SoC 176 0.69 ADAS-COG Change from Baseline to Week 24 N LS Mean LS Mean Diff.(97.51% CI) p-value Mild patients [MMSE (21-25)] Masitinib 4.5 mg/kg/day + SoC 63 -2.47 -2.89(-4.80, -0.99) 0.0008 Placebo + SoC 61 0.42 Moderate patients [MMSE (12-20)] Masitinib 4.5 mg/kg/day + SoC 119 -1.04 -1.74(-3.52, 0.04) 0.0284 Placebo + SoC 115 0.70 SoC = Standard of care = memantine and anticholinesteraseNote : Negative change in LS Mean of ADAS-COG means an improvement of cognition. Positive change in LS Mean of ADAS-COG means a worsening of cognition. Authorized phase 3 to support New Drug Application in case of success AB Science previously received an Investigational New Drug (IND) approval letter from the FDA and similar authorizations from several European countries to initiate Phase III study (AB21004) in patients with Alzheimer's disease. Study AB21004 is a randomized, double-blind phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild Alzheimer's disease, as an add-on therapy to standard of care, cholinesterase inhibitors and/or memantine. The study will enroll 600 patients. The objective of study AB21004 is to confirm results from the first phase 2B/3 study, AB09004, which showed that masitinib administered at 4.5 mg/kg/day significantly slowed cognitive deterioration relative to placebo and also reduced loss of functional ability in activities of daily living in the targeted AD population. Study AB21004 will evaluate the effect of masitinib on absolute change from baseline in cognition (ADAS-Cog-11) as primary endpoint and integrated AD rating scale (iADRS) and daily living (ADCS-ADL) as secondary endpoints. Expected patent protection until 2041 Based on the results from AB09004 study, AB Science filed a patent application relating to methods of treating Alzheimer's disease (i.e. a medical use patent) with its lead compound masitinib (WO2022129410A1). If granted, this patent will provide intellectual property protection for masitinib in this indication until 2041. A similar strategy was successfully applied in Amyotrophic Lateral Sclerosis, with medical use patent for masitinib in ALS being granted worldwide (press release dated June 1st 2023). References : Jia K, Shen Q, Zhang Z, et al. Masitinib attenuates neuropathological changes in acrolein-induced sAD mouse model via NF-κB/NLRP3/Caspase-1 signaling pathway. Neurosci Lett. Volume 862, 27 July 2025, 138300. Published online June 10, 2025. Li T, Martin E, Abada YS, et al. Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease. J Alzheimers Dis. 2020;76(4):1339-1345. doi:10.3233/JAD-200466 Dubois B, López-Arrieta J, Lipschitz S, et al. Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial [published correction appears in Alzheimers Res Ther. 2023 Apr 22;15(1):85. doi: 10.1186/s13195-023-01230-9.]. Alzheimers Res Ther. 2023;15(1):39. Piette F, Belmin J, Vincent H, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011;3(2):16. Published 2011 Apr 19. doi:10.1186/alzrt75 Ettcheto M, Cano A, Sanchez-López E, et al. Masitinib for the treatment of Alzheimer's disease. Neurodegener Dis Manag. 2021;11(4):263-276. doi:10.2217/nmt-2021-0019 About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB ScienceFinancial Communication & Media Relations investors@ Attachment Alz sAD Model PreClin vENG VFError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
7 hours ago
- Yahoo
Bill Gates reveals 'next phase of Alzheimer's fight' as he shares dad's personal battle
Bill Gates is speaking out about his personal experience with Alzheimer's — and his hope for progress in fighting the disease. In an essay published this week on his blog at the Microsoft co-founder and tech billionaire, 69, reflected on the difficulty of spending another Father's Day without his dad, Bill Gates Sr. The elder Gates passed away in 2020 at the age of 94 after battling Alzheimer's. Rates Of Dementia Are Lower In People Who Eat This Specific Diet, Research Shows "It was a brutal experience, watching my brilliant, loving father go downhill and disappear," Gates wrote in the blog post. Today, motivated by his own experience with the common dementia, Gates — who serves as chair of the Gates Foundation — is committed to working toward a cure for the common dementia, which currently affects more than seven million Americans, or one in nine people over 65. Read On The Fox News App In his blog, Gates expressed optimism about the "massive progress" being made in the fight against Alzheimer's and other dementias. Last year, Gates said he visited Indiana University's School of Medicine in Indianapolis to tour the labs where teams have been researching Alzheimer's biomarkers. Bill Gates Likely Had Autism As A Child, He Reveals: 'Wasn't Widely Understood' "I also got the opportunity to look under the hood of new automated machines that will soon be running diagnostics around the world," he wrote. "It's an exciting time in a challenging space." One of the biggest breakthroughs in Alzheimer's research, according to Gates, is blood-based diagnostic tests, which detect the ratio of amyloid plaques in the brain. (Amyloid plaques, clumps of protein that accumulate in the brain, are one of the hallmarks of Alzheimer's.) "I'm optimistic that these tests will be a game-changer," Gates wrote. Last month, the U.S. Food and Drug Administration (FDA) approved the first blood-based test for patients 55 years and older, as Fox News Digital reported at the time. Traditionally, Gates noted, the primary path to Alzheimer's diagnosis was either a PET scan (medical imaging) or spinal tap (lumbar puncture), which were usually only performed when symptoms emerged. The hope is that blood-based tests could do a better job of catching the disease early, decline begins. "We now know that the disease begins 15 to 20 years before you start to see any signs," Gates wrote. "A simple, accurate and easy-to-run blood test might one day make routine screening possible, identifying patients long before they experience cognitive decline," he stated. Gates said he is often asked, "What is the point of getting diagnosed if I can't do anything about it?" To that end, he expressed his optimism for the future of Alzheimer's treatments, noting that two drugs — Lecanemab (Leqembi) and Donanemab (Kisunla) — have gained FDA approval. "Both have proven to modestly slow down the progression of the disease, but what I'm really excited about is their potential when paired with an early diagnostic," Gates noted. He said he is also hopeful that the blood tests will help speed up the process of enrolling patients in clinical trials for new Alzheimer's drugs. To accomplish this, Gates is calling for increased funding for research, which often comes from federal grants. Click Here To Sign Up For Our Health Newsletter "This is the moment to spend more money on research, not less," he wrote, also stating that "the quest to stop Alzheimer's has never had more momentum." "There is still a huge amount of work to be done — like deepening our understanding of the disease's pathology and developing even better diagnostics," Gates went on. Gates pointed out that when his father had Alzheimer's, it was considered a "death sentence," but that is starting to change. "I am blown away by how much we have learned about Alzheimer's over the last couple of years," he wrote. For more Health articles, visit "I cannot help but be filled with a sense of hope when I think of all the progress being made on Alzheimer's, even with so many challenges happening around the world. We are closer than ever before to a world where no one has to watch someone they love suffer from this awful disease."Original article source: Bill Gates reveals 'next phase of Alzheimer's fight' as he shares dad's personal battle
USA Today
10 hours ago
- USA Today
When Caregiving Becomes Identity: Lynn Wenger's Real, Raw Journey Through Alzheimer's
What does it mean to love someone slowly forgetting who you are? For Lynn Wenger, the author of A Husband's Memoir: A Journey Through Alzheimer's, love wasn't just about showing up in the early days for his wife. It was about staying even when the person you knew began to fade, and every familiar rhythm was replaced with uncertainty. In the book, Lynn pulls back the curtain on a quiet transformation that took place when his wife was diagnosed with early-onset Alzheimer's at just 59 years old. He transformed from a devoted husband into a full-time caregiver, and that shift ultimately cost him. Before all this, Lynn was a self-made man from rural Iowa who built a successful career in construction consulting. Wendy was a registered nurse with a quick wit and a huge heart. She was the kind of person who showed up for her friends, volunteered at the local preschool, and still made time for church choir and book club. Together, they raised a family, built a life, and shared memories. This memoir, written in the months and years following his wife Wendy's diagnosis, isn't just about navigating the realities of Alzheimer's. It's about identity, grief, and what happens until you can't tell where love ends and caregiving begins. A Role He Never Trained For Lynn is no stranger to structure. He's a scheduler and a planner — someone who ran multi-million-dollar construction jobs with near-photographic precision. However, not even decades of professional precision or life experience could prepare him for the difficulties of caregiving. The shift from partner to caregiver was instantaneous and irreversible. Conversations grew harder. Decisions became heavier. "I wasn't just helping her," Lynn writes. "I was feeding her, dressing her, calming her down, watching for the next meltdown, trying to hold her world together while mine was quietly falling apart." The Isolation No One Sees In the outside world, Lynn kept things moving — balancing his work, organizing church events, staying involved in their local Boy Scout troop, and checking in with neighbors. But behind closed doors, life was shrinking. Time for himself became non-existent. So did the ability to sleep through the night. He wasn't just managing Wendy's care; he was carrying the emotional weight of every change. Her moods. Her confusion. Her sudden fear of water, loud noises, or unfamiliar places. Her eventual inability to recognize their own home. "There were days I couldn't even leave the room," Lynn writes. "Not because I had nowhere to go, but because she didn't want to let go of my hand." Lynn describes the kind of loneliness that only caregivers know, where you're never physically alone but constantly longing for a connection that used to be effortless. A Grief That Starts Too Soon In his reflections, Lynn speaks to a grief that begins long before a life ends. As Wendy's cognitive decline accelerated, moments of clarity became rare and precious. She could still sing along to their favorite 70s music. She could still flash her signature sense of humor. But those sparks were fleeting. "You don't just grieve the person," Lynn explains. "You grieve your life together. The future you planned. The roles you once shared." He captures the irony of being both deeply needed and gradually invisible — of loving someone who no longer knows they love you back. Regret, Real Talk, and a Little Grace Lynn's story is the unmistakable voice of a man doing his best. But also, the honesty of a man who wrestles with guilt. Guilt for the moments he spent working instead of sitting by her side. Guilt for the times he didn't recognize a symptom until it was too late. Guilt for simply needing a break. "If I could go back," he writes, "I'd trade every spreadsheet and scout meeting for one more walk around the block with her." However, Lynn doesn't let bitterness cloud his writing; he shares a unique perspective. Lynn's regrets are balanced by deep wells of grace, reminding caregivers everywhere that they're human — and doing more than enough. A Husband's Memoir: A Journey Through Alzheimer's does more than tell one couple's story. It shines a light on the hidden world of caregiving and how it involves sacrifice, resilience, humor, and heartbreak. Lynn doesn't gloss over the hard parts. Instead, he shares them so that others might feel less alone. Where Lynn Is Now Wendy passed away in early 2024 at just 64 years old. Lynn has since become an advocate for Alzheimer's awareness, supporting research and helping organize his local Walk to End Alzheimer's. He's been approached about leading support groups, especially for husbands and partners who, like him, never expected to become full-time caregivers. And he's open about the fact that he's still grieving, still figuring it all out. 'People think the hard part ends when they pass,' he says. 'But grief has its own timeline. It doesn't check your calendar.' For more information regarding Lynn and Wendy's story and to order the book, "A Husband's Memoir: A Journey Through Alzheimer's," go to: This article is for informational purposes only and does not substitute for professional medical advice. If you are seeking medical advice, diagnosis, or treatment, please consult a medical professional or healthcare provider.
